We use third-party cookies to provide support. By continuing to browse this website, you accept our privacy policy.
Stockal+Disclaimer.pdf
4 own
25 watching
Current Price
$38.98
$-1.34
(-3.32%)
1 Week Returns
3 Months Returns
1 Year Returns

Get Started with as little as $1.00

Market Capitalization
5,535.84M
52-Week High
48.82
52-Week Low
26.41
Average Volume
1.48M
Dividend Yield
--
P/E Ratio
106.6829
Market Capitalization5,535.84M
52-Week High48.82
52-Week Low26.41
Average Volume1.48M
Dividend Yield--
P/E Ratio106.6829
What does the Stockal+Disclaimer.pdf do?
Isis Pharmaceuticals, Inc. engages in the discovery and development of antisense drugs using novel drug discovery platform. The company's flagship product includes the KYNAMRO injection, which is an apo-B synthesis inhibitor for patients with...
Read More
How much money does Stockal+Disclaimer.pdf make?
News & Events about Stockal+Disclaimer.pdf.
PR Newswire
23days ago
Ionis presents positive Phase 2 data from open label extension study of donidalorsen at 2022 ACAAI Annual Meeting Ionis presents positive Phase 2 data from open label extension study of donidalorsen at 2022 ACAAI Annual Meeting PR Newswire CARLSBAD, Calif., Nov. 13, 2022 - Interim results show...
PR Newswire
28days ago
Ionis announces positive data from GSK's Phase 2b clinical study of bepirovirsen Ionis announces positive data from GSK's Phase 2b clinical study of bepirovirsen PR Newswire CARLSBAD, Calif., Nov. 8, 2022 GSK plans to advance bepirovirsen into Phase 3 development program in 1H 2023 CARLSBAD...
PR Newswire
1month ago
Ionis announces positive results from fesomersen development program Ionis announces positive results from fesomersen development program PR Newswire CARLSBAD, Calif., Nov. 4, 2022 - Positive Phase2b data fromRE-THINC ESRD study of fesomersen in patients on hemodialysis presented at Kidney Week...
PR Newswire
2 months ago
Ionis provides update on development program evaluating PCSK9 antisense medicine for the treatment of hypercholesterolemia Ionis provides update on development program evaluating PCSK9 antisense medicine for the treatment of hypercholesterolemia PR Newswire CARLSBAD, Calif., Sept. 23, 2022 ION449...
Frequently Asked Questions
Frequently Asked Questions
What is Stockal+Disclaimer.pdf share price today?
plus_minus_icon
Can Indians buy Stockal+Disclaimer.pdf shares?
plus_minus_icon
How can I buy Stockal+Disclaimer.pdf shares from India?
plus_minus_icon
Can Fractional shares of Stockal+Disclaimer.pdf be purchased?
plus_minus_icon
What are the documents required to start investing in Stockal+Disclaimer.pdf stocks?
plus_minus_icon
What is today’s traded volume of Stockal+Disclaimer.pdf?
plus_minus_icon
What is today’s market capitalisation of Stockal+Disclaimer.pdf?
plus_minus_icon
What is the 52-Week High and Low Range of Stockal+Disclaimer.pdf?
plus_minus_icon
What percentage is Stockal+Disclaimer.pdf down from its 52-Week High?
plus_minus_icon
What percentage is Stockal+Disclaimer.pdf up from its 52-Week Low?
plus_minus_icon
Current Price
$38.98
$-1.34
(-3.32%)
1 Week Returns
3 Months Returns
1 Year Returns

Get Started with as little as $1.00

Get Started with as little as $1.00